A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ProAct
- Sponsors AbbVie
- 10 Jul 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 10 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated